----

----

| [X] | QUARTERLY      REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF      1934 |
|-----|---------------------------------------------------------------------------------------------|

| [  ] | TRANSITION      REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE  ACT |
|----------------|-----------------------------------------------------------------------|

| Colorado                               |   | 84-1509950               |
|----------------------------------------|--------|--------------------------|
| (State      or other jurisdiction      |   | (IRS      Employer       |
| of      incorporation or organization) |   | Identification      No.) |

----

----

----

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Page      Number |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| PART      I.                      FINANCIAL      INFORMATION                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |             |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |             |
| Item      1.                                Consolidated      Financial Statements                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |             |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |             |
| Consolidated      Balance Sheets                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 3                |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |             |
| Consolidated      Statements of      Operations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 5                |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |             |
| Consolidated      Statements of Cash      Flows                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 6                |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |             |
| Consolidated      Statements of Comprehensive Loss                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 7                |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |             |
| Consolidated      Statement of Stockholders’ (Deficit)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 8                |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |             |
| Notes      to Unaudited Consolidated Financial      Statements                                                                                                                                                                                                                                                                                                                       | 9                |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |             |
| Item      2.                                Management's      Discussion and Analysis of Financial Condition and Plan of      Operations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 13               |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |             |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |             |
| Item      3.                                Quantitative      and Qualitative Disclosures about Market Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 17               |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |             |
| Item      4.                                Controls      and Procedures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 17               |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |             |
| Part      II.                      OTHER      INFORMATION                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |             |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |             |
| Item      1.                                Legal      proceedings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 18               |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |             |
| Item      2.                                Unregistered      Sales of Equity Securities and Use of Proceeds                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 18               |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |             |
| Item      3.                                Defaults      upon Senior Securities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 18               |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |             |
| Item      4.                                Submission      of Matters to a Vote of Security      Holders                                                                                                            | 18               |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |             |
| Item      5.                                      Other Information                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 18               |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |             |
| Item      6.                                Exhibits      and Reports of Form 8-K                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 18               |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |             |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |             |
| SIGNATURES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 19               |

----

| Medical      International Technology, Inc. |     Quarterly      Financial Report |
|---------------------------------------------|---------------------------------------------------------|

| CONSOLIDATED BALANCE SHEET                                                             |   |
|----------------------------------------------------------------------------------------|--------|
|                                                                                   |   |
|                                                                                   |   |
|                                                                                   |   | March 31, 2008 |   |   | September 30, 2007 |   |
|                                                                                   |   | (Unaudited) |   |   | (Audited) |   |
| Assets                                                                                 |   |   |   |   |   |   |
|                                                                                   |   |   |   |   |   |   |
|         Current Assets                                                       |   |   |   |   |   |   |
|     Cash      and cash equivalents                                 |   | $ | 448,955 |   |   | $ | 187,536 |   |
|     Accounts      receivable                                       |   |   | 6,176 |   |   |   | 6,937 |   |
|     Inventories                                                    |   |   | 184,628 |   |   |   | 194,826 |   |
|     Research credit      receivable                                |   |   | 113,829 |   |   |   | 127,718 |   |
|     Prepaid      expenses                                          |   |   | --- |   |   |   | 2,764 |   |
|                                                                                   |   |   |   |   |   |   |   |   |
| Total      Current Assets                                                              |   |   | 753,588 |   |   |   | 519,781 |   |
|                                                                                   |   |   |   |   |   |   |   |   |
|         Property and Equipment                                               |   |   |   |   |   |   |   |   |
|     Tooling      and machinery                                     |   |   | 228,599 |   |   |   | 225,175 |   |
|     Furniture and      office equipment                            |   |   | 133,014 |   |   |   | 133,014 |   |
|     Leasehold      improvements                                    |   |   | 22,163 |   |   |   | 22,163 |   |
|                                                                                   |   |   | 383,776 |   |   |   | 380,352 |   |
|                                                                                   |   |   |   |   |   |   |   |   |
|     Less      accumulated depreciation                             |   |   | (272,949 | ) |   |   | (245,536 | ) |
|                                                                                   |   |   | 110,827 |   |   |   | 134,816 |   |
|   Other      Assets                                                          |   |   |   |   |   |   |   |   |
|     Patents      (net accumulated amortization of $1,165 and $932) |   |   | 865 |   |   |   | 1,098 |   |
|                                                                                   |   |   |   |   |   |   |   |   |
| Total      Assets                                                                      |   | $ | 865,280 |   |   | $ | 655,695 |   |
|                                                                                   |   |   |   |   |   |   |   |   |

----

| Medical      International Technology, Inc. |     Quarterly      Financial Report |
|---------------------------------------------|---------------------------------------------------------|

| CONSOLIDATED BALANCE      SHEET                                      |   |
|----------------------------------------------------------------------|--------|
|                                                                 |   | March 31, 2008 |   |   | September 30, 2007 |   |
|                                                                 |   | (Unaudited) |   |   | (Audited) |   |
|                                                                 |   |   |   |   |   |   |
| Liabilities      and Stockholders' Equity (Deficit)                  |   |   |   |   |   |   |
| Current      Liabilities                                             |   |   |   |   |   |   |
|     Unearned      income                         |   | $ | 1,299,970 |   |   | $ | 7,494 |   |
|     Accounts      payable and accrued expenses   |   |   | 139,987 |   |   |   | 298,152 |   |
|     Loans      payable - related parties         |   |   | --- |   |   |   | 49,696 |   |
|     Current      portion of long-term debts      |   |   | 19,239 |   |   |   | 283,154 |   |
|                                                                 |   |   | 1,459,196 |   |   |   | 638,496 |   |
| Long-Term      Debts                                                 |   |   | 10,354 |   |   |   | 14,261 |   |
|                                                                 |   |   |   |   |   |   |   |   |
|                                                                 |   |   |   |   |   |   |   |   |
|                                                                 |   |   |   |   |   |   |   |   |
| Total      Liabilities                                               |   |   | 1,469,550 |   |   |   | 652,757 |   |
|                                                                 |   |   |   |   |   |   |   |   |
| Stockholders'      Equity (Deficit)                                  |   |   |   |   |   |   |   |   |
| Preferred      stock, $.0001 par value; 3,000,000 shares authorized; |   |   |   |   |   |   |   |   |
| None      issued and outstanding as of March 31, 2008                |   |   |   |   |   |   |   |   |
|                                                                 |   |   |   |   |   |   |   |   |
| Common      stock, $.0001 par value; 100,000,000 shares authorized;  |   |   |   |   |   |   |   |   |
| Issued      and outstanding 27,058,663 shares as of March 31, 2008   |   |   | 2,706 |   |   |   | 2,706 |   |
|                                                                 |   |   |   |   |   |   |   |   |
| Additional      paid-in capital                                      |   |   | 6,804,339 |   |   |   | 6,804,339 |   |
| Deficit                                                              |   |   | (7,426,362 | ) |   |   | (6,971,531 | ) |
| Other      comprehensive income (loss)                               |   |   | 15,047 |   |   |   | 167,424 |   |
|                                                                 |   |   |   |   |   |   |   |   |
| Total      Stockholders' Equity (Deficit)                            |   |   | (604,270 | ) |   |   | 2,938 |   |
|                                                                 |   |   |   |   |   |   |   |   |
|                                                                 |   |   |   |   |   |   |   |   |
| Total      Liabilities and Stockholders' Equity (Deficit)            |   | $ | 865,280 |   |   | $ | 655,695 |   |
|                                                                 |   |   |   |   |   |   |   |   |

----

| Medical      International Technology, Inc. |     Quarterly      Financial Report |
|---------------------------------------------|---------------------------------------------------------|

|                                               |   | Three-Months      Period EndedMarch      31, |       |   | Six-Months      Period EndedMarch      31, |   |
|----------------------------------------------------|--------|----------------------------------------------|------------|--------|--------------------------------------------|--------|
|                                               |   | 2008(Unaudited)                              |       |   | 2007(Unaudited)                            |   |   | 2008(Unaudited) |   |   | 2007(Unaudited) |   |
| Sales                                              |   | $                                            | 46,915     |   |                                       | $      | 60,045 |   |   | $ | 165,507 |   |   | $ | 107,610 |   |
| Cost      of sales                                 |   |                                         | ( 47,932   | )      |                                       |   | (26,237 | ) |   |   | (99,331 | ) |   |   | ( 52,373 | ) |
| Gross      profit (loss)                           |   |                                         | (1,017     | )      |                                       |   | 33,808 |   |   |   | 66,176 |   |   |   | 55,237 |   |
|                                               |   |                                         |       |   |                                       |   |   |   |   |   |   |   |   |   |   |   |
| Research      and development costs                |   |                                         | 125,989    |   |                                       |   | 27,299 |   |   |   | 181,053 |   |   |   | 58,158 |   |
| Selling,      general, and administrative expenses |   |                                         | 164,045    |   |                                       |   | 109,496 |   |   |   | 336,104 |   |   |   | 372,064 |   |
|                                               |   |                                         | 290,034    |   |                                       |   | 136,795 |   |   |   | 517,157 |   |   |   | 430,222 |   |
|                                               |   |                                         |       |   |                                       |   |   |   |   |   |   |   |   |   |   |   |
|  Loss      from operations                    |   |                                         | (291,051   | )      |                                       |   | (102,987 | ) |   |   | (450,981 | ) |   |   | (374,985 | ) |
|                                               |   |                                         |       |   |                                       |   |   |   |   |   |   |   |   |   |   |   |
| Other      Income (Expense)                        |   |                                         |       |   |                                       |   |   |   |   |   |   |   |   |   |   |   |
| Interest      income                               |   |                                         | 11,499     |   |                                       |   | --- |   |   |   | 12,267 |   |   |   | --- |   |
| Interest      expense                              |   |                                         | (2,005     | )      |                                       |   | (5,351 | ) |   |   | (16,117 | ) |   |   | (10,823 | ) |
|                                               |   |                                         | 9,494      |   |                                       |   | (5,351 | ) |   |   | (3,850 | ) |   |   | (10,823 | ) |
|                                               |   |                                         |       |   |                                       |   |   |   |   |   |   |   |   |   |   |   |
| Net      Loss                                      |   | $                                            | (281,557   | )      |                                       | $      | (108,338 | ) |   | $ | (454,831 | ) |   | $ | (385,808 | ) |
|                                               |   |                                         |       |   |                                       |   |   |   |   |   |   |   |   |   |   |   |
| Basic      (loss) per share                        |   | $                                            | (0.01      | )      |                                       | $      | (0.01 | ) |   | $ | (0.02 | ) |   | $ | (0.03 | ) |
|                                               |   |                                         |       |   |                                       |   |   |   |   |   |   |   |   |   |   |   |
| Basic      weighted average shares outstanding     |   |                                         | 27,058,663 |   |                                       |   | 11,982,887 |   |   |   | 27,058,663 |   |   |   | 11,982,887 |   |
|                                               |   |                                         |       |   |                                       |   |   |   |   |   |   |   |   |   |   |   |
|                                               |   |                                         |       |   |                                       |   |   |   |   |   |   |   |   |   |   |   |
|                                               |   |                                         |       |   |                                       |   |   |   |   |   |   |   |   |   |   |   |
|                                               |   |                                         |       |   |                                       |   |   |   |   |   |   |   |   |   |   |   |
|                                               |   |                                         |       |   |                                       |   |   |   |   |   |   |   |   |   |   |   |
|                                               |   |                                         |       |   |                                       |   |   |   |   |   |   |   |   |   |   |   |

----

| Medical      International Technology, Inc. |     Quarterly      Financial Report |
|---------------------------------------------|---------------------------------------------------------|

| CONSOLIDATED      STATEMENTS OF CASH FLOWS                                                |   |
|-------------------------------------------------------------------------------------------|--------|
|                                                                                      |   |
|                                                                                      |   |
|                                                                                      |   |
|                                                                                      |   |   |   |
|                                                                                      |   | Six-Months      Period EndedMarch      31, |   |
|                                                                                      |   | 2008 |   |   | 2007 |   |
| Cash      Flows from Operating Activities                                                 |   | (Unaudited) |   |   | (Unaudited) |   |
|        Net Loss                                                                      |   | $ | (454,831 | ) |   | $ | (385,808 | ) |
|        Adjustments to reconcile net loss to net cash                                 |   |   |   |   |   |   |   |   |
|          Used in operating activities:                                     |   |   |   |   |   |   |   |   |
|     Depreciation      and amortization expense                        |   |   | 27,647 |   |   |   | 22,140 |   |
|     Common      stock issued for consulting and legal services        |   |   | - |   |   |   | 173,796 |   |
|     (Increase)      decrease in Assets                                |   |   |   |   |   |   |   |   |
|     (Increase)      decrease in accounts receivable                   |   |   | 761 |   |   |   | (1,113 | ) |
|     Increase      (decrease) in advances to related corporations      |   |   | - |   |   |   | --- |   |
|     (Increase)      decrease in inventories                           |   |   | 10,198 |   |   |   | 13,744 |   |
|     (Increase)      decrease in research tax credit receivable        |   |   | 13,889 |   |   |   | 117,839 |   |
|     (Increase)      decrease in prepaid expenses                      |   |   | 2,764 |   |   |   | (40,650 | ) |
|     Increase      (decrease) in Liabilities                           |   |   |   |   |   |   |   |   |
|     Increase      (decrease) in unearned income                       |   |   | 1,292,476 |   |   |   | 32,544 |   |
|     Increase      (decrease) in accounts payable and accrued expenses |   |   | (158,165 | ) |   |   | (17,062 | ) |
|     Net      Cash Provided by (Used in) Operating Activities          |   |   | 734,739 |   |   |   | (84,571 | ) |
|                                                                                      |   |   |   |   |   |   |   |   |
| Cash      Flows from Investing Activities                                                 |   |   |   |   |   |   |   |   |
|     Equipment      acquisition                                        |   |   | (3,423 | ) |   |   | --- |   |
|     Net      cash used in investing activities                        |   |   | (3,423 | ) |   |   | --- |   |
|                                                                                      |   |   |   |   |   |   |   |   |
| Cash      Flows from Financing Activities                                                 |   |   |   |   |   |   |   |   |
|     Gross      proceeds from private offering                         |   |   | - |   |   |   | 65,000 |   |
| Reduction      in amounts due to related parties                                          |   |   | (49,696 | ) |   |   | 1,114 |   |
| Principal      reduction on small business loan                                           |   |   | (267,822 | ) |   |   | - |   |
|                                                                                      |   |   |   |   |   |   |   |   |
| Net      Cash Provided by Financing Activities                                            |   |   | (317,518 | ) |   |   | 66,114 |   |
|                                                                                      |   |   |   |   |   |   |   |   |
| Effect      of exchange rates on cash                                                     |   |   | (152,379 | ) |   |   | (17,319 | ) |
|                                                                                      |   |   |   |   |   |   |   |   |
| Net      Increase (decrease) in Cash and Cash Equivalents                                 |   |   | 260,418 |   |   |   | (1,138 | ) |
|                                                                                      |   |   |   |   |   |   |   |   |
| Beginning      Balance - Cash and Cash Equivalents                                        |   |   | 187,536 |   |   |   | 2,920 |   |
|                                                                                      |   |   |   |   |   |   |   |   |
| Ending      Balance - Cash and Cash Equivalents                                           |   | $ | 448,955 |   |   | $ | 1,782 |   |
|                                                                                      |   |   |   |   |   |   |   |   |
| Supplemental      Information:                                                            |   |   |   |   |   |   |   |   |
|                                                                                      |   |   |   |   |   |   |   |   |
|   Cash Paid      For:                                                           |   |   |   |   |   |   |   |   |
|     Interest      Expenses                                            |   | $ | 16,117 |   |   | $ | 10,823 |   |
|     Income      Taxes                                                 |   | $ | - |   |   | $ | - |   |
|                                                                                      |   |   |   |   |   |   |   |   |
|                                                                                      |   |   |   |   |   |   |   |   |

----

| Medical      International Technology, Inc. |     Quarterly      Financial Report |
|---------------------------------------------|---------------------------------------------------------|

| CONSOLIDATED      STATEMENTS OF COMPREHENSIVE LOSS                   |                       |
|----------------------------------------------------------------------|----------------------------|
|                                                                 |                       |
|                                                                 |                       |
|                                                                 |                       |
|                                                                 |                       |
|                                                                 | Second      quarter ending |   | For      the year ending |   |
|                                                                 | March      31,             |   | September      30, |   |
|                                                                 | 2008                       |   | 2007 |   |
|                                                                 |                       |   |   |   |   |   |
| Net      loss                                                        |                       | $ | (454,831 | ) |   | $ | (898,376 | ) |
| Other      comprehensive income (loss)                               |                       |   |   |   |   |   |   |   |
|     Foreign      currency translation adjustment |                       |   | 15,047 |   |   |   | 167,424 |   |
|                                                                 |                       |   |   |   |   |   |   |   |
|     Net      comprehensive income (loss)         |                       | $ | (439,788 | ) |   | $ | (730,952 | ) |
|                                                                 |                       |   |   |   |   |   |   |   |

----

| Medical      International Technology, Inc. |     Quarterly      Financial Report |
|---------------------------------------------|---------------------------------------------------------|

| CONSOLIDATED STATEMENT      OF STOCKHOLDERS’ (DEFICIT)                 |   |
|------------------------------------------------------------------------------|--------|
|                                                                         |   |
|                                                                         |   |
|                                                                         |   |
|                                                                         |   |   |   |   |   |   |   |   |   |
|                                                                         |   |   |   |   | Additional |   |   |   |   |
|                                                                         |   | Common Stock |   |   | Paid in |   |   |   |   |
|                                                                         |   | Shares |   |   | Amount |   |   | Capital |   |   | Deficit |   |
|                                                                         |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                         |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                         |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance      – September 30, 2007                                      |   |   | 27,058,663 |   |   | $ | 2,706 |   |   | $ | 6,804,339 |   |   | $ | (6,971,531 | ) |
|                                                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|     Net      loss for the period ended December 31, 2007 |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (173,274 | ) |
|                                                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance      –December 31, 2007                                        |   |   | 27,058,663 |   |   | $ | 2,706 |   |   | $ | 6,804,339 |   |   | $ | (7,144,805 | ) |
|                                                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|     Net      loss for the period ended March 31, 2008    |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (281,557 | ) |
|                                                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance      –March 31, 2008                                           |   |   | 27,058,663 |   |   | $ | 2,706 |   |   | $ | 6,804,339 |   |   | $ | (7,426,362 | ) |
|                                                                         |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |

----

| Medical      International Technology, Inc. |     Quarterly      Financial Report |
|---------------------------------------------|---------------------------------------------------------|

|                          |   | March      31, |    |   | September      30, |   |
|-------------------------------|--------|----------------|---------|--------|--------------------|--------|
|                          |   | 2008           |    |   | 2007               |   |
| Raw      materials            |   | $              | 150,338 |   |               | $      | 159,697 |   |
| Work      in process          |   |           | 25,650  |   |               |   | 13,376 |   |
| Finished      goods           |   |           | 8,640   |   |               |   | 21,753 |   |
|     Total |   | $              | 184,628 |   |               | $      | 194,826 |   |
|                          |   |           |    |   |               |   |   |   |
|                          |   |           |    |   |               |   |   |   |

----

| Medical      International Technology, Inc. |     Quarterly      Financial Report |
|---------------------------------------------|---------------------------------------------------------|

|                     |   | March      31, |         |   | September      30, |   |
|--------------------------|--------|----------------|--------------|--------|--------------------|--------|
|                     |   | 2008           |         |   | 2007               |   |
| R&D      Costs       |   | $              | 183,849      |   |               | $      | 163,712 |   |
|                          |   |           |         |   |               |   |   |   |
| Less      Credit    |   |           |  (2,796 | )      |               |   | (29,418 | ) |
|                     |   |           |         |   |               |   |   |   |
|      |   | $              | (181,053     | )      |               | $      | 134,294 |   |
|                     |   |           |         |   |               |   |   |   |
|                     |   |           |         |   |               |   |   |   |

----

| Medical      International Technology, Inc. |     Quarterly      Financial Report |
|---------------------------------------------|---------------------------------------------------------|

|                                                             |   | March      31, |    |   | September      30, |   |
|------------------------------------------------------------------|--------|----------------|---------|--------|--------------------|--------|
|                                                             |   | 2007           |    |   | 2008               |   |
|                                                             |   |           |    |   |               |   |
| Note      payable to a bank, bearing interest at prime plus 2.5% |   |           |    |   |               |   |
| secured      by equipment, due July 21, 2010.                    |   | $              | 18,094  |   |               | $      | 22,040 |   |
|                                                             |   |           |    |   |               |   |   |   |
| Note      payable to a bank, bearing interest at prime plus 3%   |   |           |    |   |               |   |   |   |
| secured      by equipment, due August 28, 2008                   |   |           | 11,499  |   |               |   | 25,375 |   |
|                                                             |   |           |    |   |               |   |   |   |
| Note      payable to an individual, unsecured and                |   |           |    |   |               |   |   |   |
| due      on demand                                               |   |           | -       |   |               |   | 250,000 |   |
|                                                             |   |           |    |   |               |   |   |   |
|                                                             |   | $              | 29,593  |   |               | $      | 297,415 |   |
|                                                             |   |           |    |   |               |   |   |   |
| Current      portion of long-term debt                           |   |           | (19,239 | )      |               |   | (283,154 | ) |
|                                                             |   |           |    |   |               |   |   |   |
| Long-term      debt                                              |   | $              | 10,354  |   |               | $      | 14,261 |   |
| Scheduled      maturities of long-term debt are as follows:      |   |           |    |   |               |   |   |   |
| March      31, 2009                                              |   |           | 19,239  |   |               |   |   |   |
| March      31, 2010                                              |   |           | 7,740   |   |               |   |   |   |
| July      31, 2010                                               |   |           | 2,614   |   |               |   |   |   |
|                                                             |   |           |    |   |               |   |   |   |
|                                                             |   |           | 29,593  |   |               |   |   |   |
|                                                             |   |           |    |   |               |   |   |   |

----

| Medical      International Technology, Inc. |     Quarterly      Financial Report |
|---------------------------------------------|---------------------------------------------------------|

----

| Medical      International Technology, Inc. |     Quarterly      Financial Report |
|---------------------------------------------|---------------------------------------------------------|

----

| Medical      International Technology, Inc. |     Quarterly      FinancialReport |
|---------------------------------------------|--------------------------------------------------------|

----

| Medical      International Technology, Inc. |     Quarterly      FinancialReport |
|---------------------------------------------|--------------------------------------------------------|

----

| Medical      International Technology, Inc. |     Quarterly      FinancialReport |
|---------------------------------------------|--------------------------------------------------------|

----

----

| Medical      International Technology, Inc. |     Quarterly      FinancialReport |
|---------------------------------------------|--------------------------------------------------------|

the company is engaged in the following legalproceedings:

----

| Medical      International Technology, Inc. |     Quarterly      FinancialReport |
|---------------------------------------------|--------------------------------------------------------|

|              | Medical International      Technology, Inc. |
|-------------------|---------------------------------------------|
|              | Registrant                                  |
|              |                                        |   |
| Date: May 9, 2008 | By:                                         | \s\    Karim Menassa |
|              |                                        | Karim      Menassa, President and Principal Executive Officer |
|              |                                        |   |
| Date: May 9, 2008 | By:                                         | \s\    Michel Bayouk |
|              |                                        | Michel      Bayouk, Secretary and Principal Accounting  Officer |